Efficacy of Remibrutinib in Patients with Chronic Spontaneous Urticaria with or Without Prior Exposure to Biologics in the Phase 3 REMIX-1 and REMIX-2 Studies

Remibrutinib, an oral, highly selective Bruton's tyrosine kinase inhibitor, demonstrated superiority vs placebo in change from baseline (CFB) in weekly Urticaria Activity Score (UAS7) at week 12 in the phase 3 REMIX studies of patients with chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines. Here, we assess remibrutinib in patients with or without prior anti-immunoglobulin E (IgE) biologic treatment in pooled analyses of the REMIX studies.